Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
respiratory-depression
Press Release
Sep 24, 2024
Enalare Receives FDA Clearance to Initiate the First Phase 1 Clinical Study of ENA-001 to Be Conducted in the United States
Read More
Press Release
Sep 10, 2024
Enalare Therapeutics Receives Additional Funding From BARDA to Further Advance the Development of Agnostic Respiratory Stimulant (ENA-001)
Read More
Press Release
Feb 15, 2024
Enalare Therapeutics Announces Publication of a Clinical Study Demonstrating the Effect of ENA-001 on Improving Propofol-Induced Depression of the Hypoxic Ventilatory Response
Read More
Press Release
Jan 19, 2021
Enalare Therapeutics Appoints Mark Coleman M.D. to Its Board of Directors
The Addition of Dr. Coleman Further Enhances the Company's Deep Medical, Enterprise Leadership, and Capital Markets Experience
Read More
Press Release
Nov 17, 2020
Enalare Therapeutics Appoints 3 New Members to Its Board of Directors
The addition of Gino Santini, Bob Yedid, and Joe Petko Significantly Expands Company's Pharmaceutical and Financial Markets Experience and Capabilities
Read More
Press Release
Nov 9, 2020
Enalare Therapeutics Appoints Daniel Motto as Chief Business Officer
Read More
Press Release
Oct 30, 2020
Enalare Therapeutics Appoints Herm Cukier as Executive Chairman, President, and CEO
Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and Chief Executive Officer.
Read More
First
Prev
1
Next
Last
